Advanced search
Publication Cover
Journal of Chemotherapy Volume 35, 2023 - Issue 2
Submit an article Journal homepage
150
Views
0
CrossRef citations to date
0
Altmetric
Anticancer Original Research Papers

BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells

Ruikai Wanga Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Anhui Medical University,Hefei, China;b Pulmonary and Critical Care Medicine, First Affiliated Hospital, Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, ChinaView further author information
,
Amin Lib Pulmonary and Critical Care Medicine, First Affiliated Hospital, Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, China;c Medical School, Anhui University of Science & Technology, Huainan, ChinaView further author information
,
Jiachang Liub Pulmonary and Critical Care Medicine, First Affiliated Hospital, Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, ChinaView further author information
,
Ming Fangb Pulmonary and Critical Care Medicine, First Affiliated Hospital, Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, ChinaView further author information
,
Yan Zhub Pulmonary and Critical Care Medicine, First Affiliated Hospital, Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, ChinaView further author information
,
Juan Huangb Pulmonary and Critical Care Medicine, First Affiliated Hospital, Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, ChinaView further author information
,
Yinjie Liub Pulmonary and Critical Care Medicine, First Affiliated Hospital, Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, ChinaView further author information
,
Long Huob Pulmonary and Critical Care Medicine, First Affiliated Hospital, Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, ChinaView further author information
&
Qinghai Youa Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Anhui Medical University,Hefei, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 95-103 | Received 14 Sep 2021, Accepted 20 Feb 2022, Published online: 03 Mar 2022

Reference

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
  • Reck M, Rabe KF. Advanced non-small-cell lung cancer. N Engl J Med. 2017;377(20):1999.
  • Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
  • Li A, Cao W, Liu X, et al. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2020;146(7):1737–1749.
  • Porta C, Paglino C, Mosca A. Targeting PI3K/akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.
  • Brown KK, Toker A. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep. 2015;7:13.
  • Ahlskog JK, Larsen BD, Achanta K, et al. ATM/ATR-mediated phosphorylation of PALB2 promotes RAD51 function. EMBO Rep. 2016;17(5):671–681.
  • Yue X, Bai C, Xie D, et al. DNA-PKcs: a multi-faceted player in DNA damage response. Front Genet. 2020;11:607428.
  • Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 2014;21(2):251–259.
  • Xu N, Lao Y, Zhang Y, et al. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol. 2012; 2012:951724.
  • Iksen Pothongsrisit S, Pongrakhananon V. Targeting the PI3K/AKT/mTOR signaling pathway in lung cancer: an update regarding potential drugs and natural products. Molecules. 2021;26(13):4100.
  • Fròsina G, Profumo A, Marubbi D, et al. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Radiat Oncol. 2018;13(1):76.
  • Mukherjee B, Tomimatsu N, Amancherla K, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012;14(1):34–43.
  • Calero R, Morchon E, Martinez-Argudo I, et al. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett. 2017; 406:1–411.
  • Marcondes NA, Terra SR, Lasta CS, et al. Comparison of JC-1 and MitoTracker probes for mitochondrial viability assessment in stored canine platelet concentrates: a flow cytometry study. Cytometry A. 2019;95(2):214–218.
  • Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.
  • Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21(1):37–50.
  • Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013;332(2):237–248.
  • Menolfi D, Zha S. ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition ≠ deletion. Cell Biosci. 2020;10:8.
  • Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–189.
  • Endo H, Inoue I, Masunaka K, et al. Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of bad. Biosci Biotechnol Biochem. 2020;84(12):2440–2447.
  • Foote KM, Blades K, Cronin A, et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013;56(5):2125–2138.
  • Sabbah DA, Hajjo R, Bardaweel SK, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020). Expert Opin Ther Pat. 2021;31(10):877–892.
  • Batool A, Majeed ST, Aashaq S, et al. Eukaryotic initiation factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin. Int J Biol Macromol. 2019;125:651–659.
  • Fang D, Hawke D, Zheng Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282(15):11221–11229.
  • Wan G, Liu Y, Zhu J, et al. SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3β/β-catenin pathway. Cell Signal. 2019;59:1–12.
  • Enriquez-Rios V, Dumitrache LC, Downing SM, et al. DNA-PKcs, ATM, and ATR interplay maintains genome integrity during neurogenesis. J Neurosci. 2017;37(4):893–905.
  • Arnoult N, Correia A, Ma J, et al. Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN. Nature. 2017;549(7673):548–552.
  • Reddy D, Kumavath R, Ghosh P, et al. Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways. Biomolecules. 2019;9(12):792.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.